

-13-

CLAIMS

1. Method for preparing a composite product comprising a step in which an active substance undergoes co-grinding with a carrier comprising N-vinyl-2-pyrrolidone/vinyl acetate copolymer.
- 5 2. Method according to claim 1, in which the carrier is N-vinyl-2-pyrrolidone/vinyl acetate.
3. Method according to claim 1, in which the co-grinding step takes place in dry conditions.
- 10 4. Method according to claim 1, in which the active substance is chosen among non steroidal anti-inflammatory agents.
5. Method according to claim 1, in which the active substance is chosen among anti-hypertensives.
- 15 6. Method according to claim 1, in which the active substance is chosen among hepato-biliary agents.
7. Method according to claim 1, in which the active substance is chosen among substances that are scarcely soluble in water environment.
- 20 8. Method according to claim 7; in which the active substance is chosen among scarcely water soluble substances having a low dissolution speed.
9. Method according to at least one of the preceding claims, in which the active substance is chosen among: anti-inflammatory agents, analgesics, relaxants, anti-microbic agents, antiseptics, acid pump inhibitors, H<sub>2</sub> antagonists, anti-emetics and anti-nausea, biliary acids, oral hypoglycemizers, diuretics, anti-hypertensives, sulfonamides, ace-inhibitors,
- 25 10. hypolipemizers, anti-mycotic agents, antihistamines, hormones, quinolone derivates, antibacterial agents, beta-lactame and fluoroquinolone antibiotics, antiviral agents, anti-neoplastic agents, immuno-modulators and immuno-suppressors, anti-gout agents,

-14-

anesthetics, analgesics, antipyretics, 5HT<sub>1</sub> agonists, anti-Parkinson agents, anti-psychotic agents, tranquilizers, antidepressants, anti-parasitic agents, non-cortisone anti-allergic agents, anti-  
5 asthmatic agents, anti-glaucoma agents, inhibitors of carbonic anhydrase or beta-blockers.

10. Method according to claim 9, in which the active substance is chosen among: paracetamol, nifedipine, piroxicam, ibuprofen, sulindac, diclofenac, alclofenac, ketorolac, indomethacine, naproxen, fenoprofen, flurbiprofen, ketoprofen, cimetidine, ranitidine, mesalazine, ursodeoxycholic acid, mefenamic acid, simvastatin, megestrol acetate, lorazepam, diazepam, cyclosporin, ubiquinone, tolbutamide, ketanserine, furosemide, nicergoline, losartan, econazole, miconazole, taxol, progesterone, prednisolone, beclometasone, nalidixic acid, finasteride, ciprofloxacin, ofloxacin, lomefloxacin, methotrexate, etoposide, daunorubicine, tamoxifen, allopurinol, clodronic acid, sumatriptan, carbamazepine, clorpromazine, clozapine, sulpiride, buspirone, fluoxetine, citalopram, caffeine, metronidazole, acetazolamide.

11. Method according to at least one of the preceding claims, in which the active substance and N-vinyl-2-pyrrolidone/vinyl acetate copolymer are present in a weight ratio between 1:200 and 10:1; preferably between 1:100 and 5:1.

12. Composite product that can be obtained from a process according to at least one of the claims 1 to 11.

13. Pharmaceutical composition comprising the composite product according to claim 12.

14. Pharmaceutical composition according to claim 13,

-15-

in which the pharmaceutical form is chosen among:  
tablet, capsule, pellet, syrup and solution.

15. Method for preparing the pharmaceutical  
composition according to claim 13 comprising a step in  
5 which the composite product according to claim 12 is  
mixed with excipients or pharmaceutically acceptable  
additives.

16. Use of an active substance and of a carrier  
comprising N-vinyl-2-pyrrolidone/vinyl acetate for  
10 preparing a pharmaceutical formulation.